Posted by Michael Wonder on 28 Sep 2017
Sanofi and Regeneron announce approval of Dupixent (dupilumab) to treat adult patients with moderate-to-severe atopic dermatitis in the European Union
27 September 2017 - First targeted biologic in the European Union to receive marketing authorisation for use in atopic dermatitis.
Sanofi and Regeneron Pharmaceuticals today announced that the European Commission has granted marketing authorisation for Dupixent (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
The approval of Dupixent was based on studies from the global LIBERTY AD clinical trial program, which included nearly 3,000 patients. LIBERTY AD studies including SOLO 1, SOLO 2, CHRONOS, SOLO-CONTINUE and CAFÉ.
